Aligned Genetics, Inc.
Financials
Valuation Metrics
Aligned Genetics, Inc.'s Market Cap is ₩437B. At end of 2025 it was ₩550B. Ranked #1863 of 2,421 in KR market (top 77%), #1150 of 1,640 on KOSDAQ (top 70%), #196 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 85%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 43.65B KRW | KR#1,863/2,421 Sec#196/231 |
| Revenue | 16.16B KRW | KR#2,196/2,421 Sec#162/231 |
| Net Income | 4.64B KRW | KR#1,240/2,421 Sec#85/231 |
| Total Assets | 60.44B KRW | KR#2,100/2,421 Sec#183/231 |
| Net Assets | 39.20B KRW | KR#2,061/2,421 Sec#181/231 |
| Employees | 66 | KR#1,921/2,421 Sec#168/231 |
| Value | ||
| P/E | 9.40x | KR#764/2,421 Sec#38/231 |
| P/B | 1.11x | KR#1,558/2,421 Sec#103/231 |
| PEG | 0.24x | KR#585/2,421 Sec#33/231 |
| P/S | 2.70x | KR#1,946/2,421 Sec#115/231 |
| EV/EBITDA | 18.41x | KR#964/2,421 Sec#56/231 |
| FCF Yield | -2.77% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 11.84% | KR#486/2,421 Sec#33/231 |
| ROA | 7.68% | KR#460/2,421 Sec#36/231 |
| Op. Margin | 15.63% | KR#278/2,421 Sec#26/231 |
| Revenue Growth | -5.88% | KR#1,810/2,421 Sec#172/231 |
| Earnings Growth | 39.94% | KR#595/2,421 Sec#38/231 |
| Financial Health | ||
| Debt Ratio | 54.17% | KR#1,021/2,421 Sec#119/231 |
| Total Debt | 14.31B KRW | KR#1,511/2,421 Sec#129/231 |
| FCF | -1.21B KRW | KR#1,294/2,421 Sec#98/231 |
| Cash | 11.44B KRW | KR#1,622/2,421 Sec#138/231 |
| Current Ratio | 5.43x | KR#256/2,421 Sec#48/231 |
| Net Debt/EBITDA | 1.14x | KR#751/2,421 Sec#51/231 |
| Performance | ||
| 1Y Return | -8.22% | KR#928/2,421 Sec#58/231 |
| 1M Return | -0.16% | KR#1,254/2,421 Sec#94/231 |
| From 52W High | -49.26% | KR#1,362/2,421 Sec#104/231 |
| 1Y MDD | -55.70% | KR#1,244/2,421 Sec#102/231 |
| Trading | ||
| Volume | 13,394 shares | KR#1,788/2,421 Sec#178/231 |
| Trading Value | 40.5M KRW | KR#1,916/2,421 Sec#192/231 |
| Foreign Own. | 2.57% | KR#1,433/2,421 Sec#134/231 |
| Per Share | ||
| EPS | 326 KRW | KR#1,141/2,421 Sec#78/231 |
| BPS | 2,757 KRW | KR#1,910/2,421 Sec#147/231 |
Company Info
Alligned, established in 2008 as a technology venture company developing, producing, and selling advanced equipment and reagents for life science research and diagnostics worldwide, was listed on the KOSDAQ market in 2016. It operates overseas sales corporations and branches in the United States, Europe, and Japan. Based on convergence technologies including bio, optics, electricity, electronics, and software, its main products are automatic cell counting systems, biological tissue clearing and imaging systems, and digital cell imaging systems.